Quanta Fluid Solutions Ltd – Appointment of new Chief Executive Officer
8 January 2014 | By Quanta Fluid Solutions Ltd
Quanta Fluid Solutions Ltd announces the appointment of John E. Milad as Chief Executive Officer...
List view / Grid view
News
Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib
7 January 2014 | By Johnson & Johnson
Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…
Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration
7 January 2014 | By Boehringer Ingelheim
Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program...
Sanofi to expand access to Clinical Trial Data
2 January 2014 | By Sanofi
“Sanofi has a history of contributing in this collective effort of sharing clinical trial data and results with researchers and patients with initiatives such as Project Data Sphere..."
GSK adds detailed clinical trial data to multi-sponsor request system as part of continued commitment to data transparency
2 January 2014 | By GlaxoSmithKline
GSK became the first company to launch an online system enabling external researchers to request access to the detailed data that sit behind its clinical trial results...
Romosozumab Phase 2 data published In New England Journal Of Medicine show significant increases in bone mineral density at both spine and hip
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
Lundbeck scientists part of group achieving breakthrough in understanding schizophrenia
23 December 2013 | By Lundbeck
New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...
Daiichi Sankyo receives approval for additional indication of anticancer agent Topotecin® injection
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo Company has received supplemental new drug application (sNDA) approval for Topotecin® injection 40 mg and 100 mg (irinotecan hydrochloride hydrate) for unresectable pancreatic cancer.
Daiichi Sankyo receives approval for the use of Inavir® to prevent influenza
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo has received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate)...
Roche and Chugai’s new subcutaneous formulation of RoActemra® (tocilizumab) gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
Merck announces launch of a new business focused on comprehensive, evidence-based weight management interventions in the U.S.
20 December 2013 | By Merck
This business is based on providing weight management interventions that combine a structured diet, behavior coaching...
Daiichi Sankyo receives approval for the use of Inavir® to prevent influenza
20 December 2013 | By Daiichi Sankyo
Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan...
Sanofi and Regeneron announce collaboration with American College of Cardiology for PCSK9 inhibitor clinical program
19 December 2013 | By Sanofi
Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment...
Sandoz begins Phase III clinical trial for biosimilar adalimumab
19 December 2013 | By Sandoz
Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio...
